OC
ORMP icon

Oppenheimer & Co’s Oramed Pharmaceuticals ORMP Stock Holding History

Oppenheimer & Co’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50,000
Closed -$229K – 1436
2022
Q2 		$229K Buy
50,000
+2,550
+5% +$13.6K ﹤0.01% 1210
2022
Q1 		$410K Buy
47,450
+7,450
+19% +$76.3K 0.01% 1077
2021
Q4 		$571K Buy
40,000
+5,200
+15% +$109K 0.01% 984
2021
Q3 		$765K Buy
34,800
+8,325
+31% +$142K 0.01% 838
2021
Q2 		$354K Sell
26,475
-1,325
-5% -$15.2K 0.01% 1173
2021
Q1 		$282K Buy
27,800
+15,800
+132% +$130K 0.01% 1208
2020
Q4 		$51K Buy
+12,000
New +$39K ﹤0.01% 1328

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Oppenheimer & Co's ORMP Position: Q3 2022 in Review

Oppenheimer & Co sold out of Oramed Pharmaceuticals (ORMP) in Q3 2022, closing a stake of 50,000 shares — an estimated $229K sold.

Oppenheimer & Co first reported a position in ORMP in Q4 2020 and held it in 7 quarters. The position peaked at $765K in Q3 2021. 71 funds tracked by Wall St. Rank hold ORMP as of Q3 2022.

  • Oppenheimer & Co reported no remaining Oramed Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Oppenheimer & Co sold 50,000 Oramed Pharmaceuticals shares in Q3 2022, an estimated $229K.
  • Oppenheimer & Co first reported a position in Oramed Pharmaceuticals in Q4 2020 and held it in 7 quarters.
  • Oppenheimer & Co's Oramed Pharmaceuticals position peaked at $765K in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2022.

Based on Oppenheimer & Co's 13F filing for Q3 2022, filed 14 Nov 2022.